Classical radial artery access

Classical radial artery access refers to the traditional method of accessing the radial artery for percutaneous coronary angiography. This technique has been a standard in interventional cardiology since the 1990s. According to the 2024 DORA randomized control trial, both classical and dorsal access techniques show equal procedural success rates. However, classical access is associated with higher incidences of radial artery occlusion (RAO), spasm, and post-procedure pain. In the context of medical device risk management, this procedure must be evaluated under ISO 14121 and ISO 14971 standards to ensure patient safety and regulatory compliance. The distinction between these techniques is critical for clinical risk-benefit analysis, which is a core requirement for CE marking under EU MDR. Companies must be closely monitoring these outcomes to meet the post-market surveillance obligations.

In medical device enterprises, classical radial artery access risks are managed through a three-step framework: First, Risk Identification—mapping the specific risks of the classical approach (e.g., RAO, spasm) against ISO 14971 risk-adjusted-benefit analysis. Second, Risk Control—implementing procedural changes or device-specific mitigations (e.g., using specific sheath sizes or anti-spasm medications). Third, Clinical Evaluation—using clinical data from studies like the DORA trial to validate the safety profile. A real-world application seen in European hospitals shows that transitioning to dorsal access can reduce RAO by up to 25%, which directly impacts hospital-level risk-adjusted cost-effectiveness. For manufacturers, this means the classical approach must be documented with clear risk-mitigation strategies to be considered 'safe and effective' under regulatory scrutiny.

Taiwan enterprises face three primary challenges: 1. Regulatory Transition—the shift from local TFDA requirements to EU MDR standards necessitates a complete overhaul of technical documentation. 2. Clinical Evidence Gaps—many companies lack the robust clinical data needed to justify the classical approach's risk-benefit profile compared to newer techniques. 3. Cultural Resistance—clinicians may be reluctant to change established classical protocols. To overcome these, companies should: A) Invest in clinical studies to provide quantitative evidence of safety and efficacy. B) Implement a phased approach, starting with pilot programs in selected hospitals. C) Establish a dedicated regulatory affairs team with expertise in both TFDA and EU MDR to ensure continuous compliance. The priority should be the establishment of a robust Post-Market Surveillance (PMS) system to track RAO rates and other adverse events.

Winners Consulting Services Co., Ltd. specializes in helping Taiwan enterprises navigate the complexities of medical device risk management, including Classical radial artery access-related regulatory compliance. We provide end-to-end support—from ISO 14971 risk assessment to EU MDR technical file preparation—ensuring your products meet international standards within 90 days. With over 100 successful projects, we help you avoid costly delays in market access. Request a free mechanism diagnosis: https://winners.com.tw/contact